Can carboplatin or etoposide replace actinomycin-D for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia?

摘要

Objective. To evaluate the impact of periodic shortage of actinomycin-D (Act-D) in the treatment of Brazilian patients with low-risk gestational trophoblastic neoplasia (GTN) after methotrexate and folinic acid rescue (MTX/FA) resistance, treated alternately with carboplatin or etoposide as a second-line regimen.